Form 4 Filing for Agios Pharmaceuticals, Inc.

This filing details transactions by Cecilia Jones, the Chief Financial Officer of Agios Pharmaceuticals, Inc. On June 18, 2026, Jones disposed of 3,000 performance share units, with a post-transaction balance of 9,000 units. These units represent a contingent right to receive common stock, with vesting tied to clinical and research milestones. The shares related to one such milestone are set to vest on December 31, 2027, contingent on continued service. Additionally, Jones acquired 3,000 restricted stock units, also representing a contingent right to receive common stock, with a post-transaction balance of 3,000 units. The transactions were reported on Form 4.